Acadia Pharmaceuticals Email Format

Pharmaceutical Manufacturing
501-1,000 employees
San Diego, CA, USA

Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative treatments for neurological disorders and rare diseases worldwide.

Find contacts at Acadia Pharmaceuticals

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@acadia-pharm.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
1993
Headquarters
San Diego, CA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Key Executives
Catherine Owen Adams (Chief Executive Officer), Mark C. Schneyer (Executive Vice President, Chief Financial Officer), Scott Cenci (Senior Vice President, Chief Information and Data Officer)

Tech Stack

Snowflake

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Acadia Pharmaceuticals?

Acadia Pharmaceuticals uses the first.last format, so Jane Smith would be jane.smith@acadia-pharm.com.

What FDA-approved products does Acadia Pharmaceuticals currently sell?

Acadia Pharmaceuticals has two FDA-approved products in its commercial portfolio: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, including a newer DAYBUE STIX powder formulation approved in December 2025.

How many people work at Acadia Pharmaceuticals?

Acadia Pharmaceuticals has approximately 1,005 employees, with its headquarters based in San Diego, California.

Who leads Acadia Pharmaceuticals as CEO in 2026?

Catherine Owen Adams serves as Chief Executive Officer of Acadia Pharmaceuticals in 2026. You can use Clay to find and verify her contact details or to enrich a list of Acadia Pharmaceuticals leadership contacts.

What does Acadia Pharmaceuticals' late-stage pipeline focus on beyond its approved treatments?

Beyond its approved products, Acadia Pharmaceuticals is advancing remlifanserin for Alzheimer's disease psychosis and Lewy body dementia psychosis, with Phase 2 RADIANT study top-line results expected in the second half of 2026.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles